Titanium
Dioxide
The pigment cycle finally turned. Chemours and Tronox both make the white that goes in paint, plastic and paper — and both stocks are still down more than half over three years. But one of them stopped being a TiO2 company, and the other one has $3.0 billion of net debt against an $866 million market cap. Same commodity, two completely different bets.
The Setup
Three things turned at once in 2026, and they are the reason both companies are guiding sequentially higher into Q3 despite a seasonally weaker quarter. None of them are demand recovery.
Increases Are Sticking
Tronox put through 5% sequential increases in both TiO2 and zircon in Q2 and has announced another round already in effect for Q3. Chemours is roughly 5% up year-to-date on TiO2 with a further global increase effective June 1.
After three years of price-taking, both are guiding to further mid-single-digit sequential increases — the first time in this cycle that pricing, not volume, carries the quarter.
Antidumping Duties Bite
Tronox's CEO is explicit that share gains are coming from "regions that successfully implemented antidumping tariffs on the import of Chinese TiO2," and cites trade defense measures and structural shifts as a direct driver of Q2 volumes.
Q2 TiO2 volumes were the highest since Q2 2022 — a four-year high reached without any broad construction or coatings recovery.
Capacity Is Leaving
In January, Tronox announced the permanent closure of its 46,000-tonne Fuzhou, China plant, blaming weak Chinese demand, sulfur costs, and "Chinese competitors' continued excess production and unsustainable pricing." Roughly 550 staff affected.
Cost: $60–80M of charges (of which $35–45M non-cash). Benefit: over $15M of annual savings, and one less marginal producer.
Head To Head
Quarter ended June 30, 2026, as reported August 4 (Chemours) and August 5 (Tronox). Market data as of August 26, 2026.
| Metric | CC · Chemours | TROX · Tronox |
|---|---|---|
| Share price | $15.73 | $5.42 |
| Market cap | $2.37B150.5M shares | $866M159.7M shares |
| 3-year return | −53%low of $9.40 | −58%low of $2.88 |
| Q2 revenue | $1.58Bapproximately flat y/y | $868M+19% y/y, +14% q/q |
| Q2 adj. EBITDA | $247M15.6% margin | $73M8.4% margin |
| Q2 GAAP result | −$274M−$1.81/sh, legal & environmental reserves | −$171M−$1.07/sh, incl. $103M tax valuation allowance |
| Q2 free cash flow | Positive+128% y/y, 46% conversion | +$60Minventory cut $120M |
| Net leverage | 4.4xtarget ~3.8x by year-end | 11.4x$3.0B net debt |
| Next major maturity | 2032term loan B extended | 2029no financial covenants on TLs/bonds |
| Q3 adj. EBITDA guide | $175–205M | $95–115M |
| TiO2 as % of profit | ~19%of segment EBITDA | ~100%pure play + zircon |
Chemours
The thing to understand about CC is that it is not a TiO2 company anymore — it is a refrigerants company with a large pigment division attached. The 2026 story is legal, not commercial: the PFAS liability that has hung over the equity for a decade is being converted into a payment schedule.
Where the profit actually is
Bars show Q2 segment adjusted EBITDA, scaled to the largest. TiO2 is 41% of sales and under a fifth of profit. Refrigerants carry 86% of segment EBITDA at a 36% margin — which is why the TiO2 cycle turning matters less to CC than the headline suggests.
The growth line nobody talks about: APM's Performance Solutions rose 8% on data center and semiconductor demand, including liquid cooling.
The PFAS endgame
- August 2025Cost-sharing MOU with DuPont and Corteva covering future eligible PFAS liabilities — the three-way split that caps any single party's exposure.
- Q2 2025New Jersey settlement and related reserves drive a $380M quarterly loss.
- June 23, 2026EPA + West Virginia DEP consent decree. $22.5M civil penalty over three annual installments, plus $90M across 15 years for emissions mitigation and drinking water projects at Washington Works, Fayetteville Works and Chambers Works. Subject to public comment and court approval. No admission of liability.
- Q2 2026The reserves for that settlement are what produced the $274M GAAP loss — partly offset by a gain on the Taiwan land sale.
The direction of travel is what matters: an open-ended, unquantifiable liability is becoming a scheduled cash cost small enough to fund out of operating cash flow.
Balance sheet repair
• $700M of 7.875% notes due 2034 priced in February (upsized from $600M), closed March — proceeds retired the 2027s and 2028s.
• Term Loan B extended from 2028 to 2032 at SOFR + 3.50%.
• $360M Kuan Yin, Taiwan land sale closed in Q2; proceeds to debt reduction.
• €180M European receivables factoring facility added.
Net leverage fell to 4.4x, guided to ~3.8x by year-end against a long-term target below 3x.
Guidance & the soft spot
FY26: sales +1% to +5%, adjusted EBITDA $775–825M, capex $250–280M, free cash flow conversion above 25%.
Q3: consolidated adjusted EBITDA $175–205M; TT $70–80M on further pricing; APM $20–30M.
The catch: TSS — the profit engine — is guided down mid-teens to 20% sequentially. Opteon aftermarket refrigerant demand in North America is weak because the channel is still digesting the initial fill from mid-2025. Whether that is an inventory correction or something structural is the single most important open question for CC.
Tronox
TROX is the clean expression of the TiO2 recovery — and the operations really are inflecting. The problem is that the equity is the thin slice at the top of a very levered structure. At $866M of market value against $3.0B of net debt, roughly 78% of the enterprise belongs to creditors.
Who owns the enterprise
• Net leverage 11.4x on a trailing twelve-month basis.
• Liquidity $527M — $194M cash plus $333M of revolver availability.
• No financial covenants on the term loans or bonds; the company does not expect to trip the springing covenant on the US revolver.
• Next significant maturity not until 2029. A short-term revolver was replaced with a longer-dated arrangement in the quarter.
• September 2025: issued $400M of 9.125% senior secured notes due 2030 — the cost of capital tells you how the credit market sees this.
No covenants and a 2029 wall are why this is a going concern rather than a restructuring. They buy time — they do not fix the leverage.
What is genuinely working
• Revenue $868M, +19% y/y and +14% q/q; TiO2 volumes the highest since Q2 2022, at the high end of guidance.
• Zircon volumes beat expectations again as industry supply stays constrained; pricing up 5% sequentially alongside TiO2.
• Cost improvement program tracking to the high end of a $125–175M annual run-rate savings target by end-2026.
• Free cash flow +$60M, with inventory cut roughly $120M to its lowest level since June 2024.
• Restarting a furnace and bringing the West Mine back online at Namakwa to rebuild zircon inventory — a real demand signal, not a cost cut.
• Q3 adjusted EBITDA guided to $95–115M, a step up from $73M, on mid-single-digit TiO2 and mid-to-high single-digit zircon price increases against a normal seasonal volume decline.
• The $0.05 quarterly dividend has been maintained throughout.
The rare earths option
Tronox mines mineral sands that contain monazite, a rare-earth-bearing mineral it already handles. It is assessing a cracking and leaching facility in Australia to process monazite-bearing tailings into feedstock for a potential US refinery producing both heavy and light rare earth oxides.
The definitive feasibility study concludes by Q3 2027. Management is explicit that it will pursue development pathways that "prioritize returns and limit incremental leverage," and is engaging partners and funding sources rather than balance-sheeting it.
Real optionality on a supply chain the West wants diversified — but distant, unfunded, and not a 2026 or 2027 earnings event.
The GAAP tell
The $171M net loss includes a $103M tax valuation allowance. That is an accounting judgment that future taxable income is not sufficiently assured to carry the deferred tax assets — in plain terms, the auditors' view of the earnings trajectory, written down in ink.
An 8.4% adjusted EBITDA margin on a 19% revenue increase also tells you how much operating leverage is still trapped: the recovery is showing up in the top line well before it reaches the bottom.
Governance note: Keith Schwarz, a 35-year KPMG audit veteran and former SEC engagement quality reviewer, joined the board and audit committee on July 29, 2026.
The Divide
Both stocks are cheap against their own history. They are not the same trade, and they do not fail the same way.
Chemours
CC works precisely because it isn't a TiO2 bet. Refrigerants throw off 36% margins and carry the company; TiO2 recovering is upside on a segment currently earning almost nothing. Meanwhile the decade-long PFAS overhang is being converted into a known payment schedule, leverage is coming down toward 3.8x, and maturities have been pushed to 2032.
You are buying a de-risking story with a free option on pigment.
What breaks it: TSS aftermarket weakness proving structural rather than an inventory correction. If Opteon demand doesn't normalize, the 86% of profit that carries this company is the problem, not the solution — and 4.4x leverage stops looking comfortable.
Tronox
If Q3's $95–115M guide annualizes and pricing holds through 2027, TROX is looking at $400M+ of EBITDA against an $866M equity — leverage compresses violently in the right direction, and the equity is the part that moves. Positive free cash flow, a four-year volume high, and $175M of cost savings all point that way.
The stock has already roughly doubled off $2.88, which is the market starting to price exactly this.
What breaks it: pricing stalls. At 11.4x net leverage there is no cushion — the equity is a thin slice and the tax valuation allowance says management's own auditors are not underwriting the recovery yet. The absence of covenants and a 2029 wall buy time, not solvency.
What To Watch
Both guided up sequentially. CC needs $175–205M; TROX needs $95–115M. The gap between guided and delivered is the cleanest read on whether pricing is actually holding.
The real test: do the TiO2 price increases survive a seasonally weak fourth quarter, or do they get given back the way every previous attempt in this cycle did?
Court approval of the Chemours EPA/WVDEP settlement, after the public comment period. Approval converts the last big PFAS unknown into a line item.
Tronox's path down from 11.4x. Watch free cash flow conversion and whether working capital keeps contributing once the inventory drawdown is exhausted.
Tronox's cracking and leaching feasibility study concludes — and with it, whether the monazite option is financeable without adding leverage.
North American Opteon aftermarket inventory. The single variable that decides whether Chemours' safety is real.
Built from primary sources: SEC filings and furnished exhibits for The Chemours Company (CIK 1627223) and Tronox Holdings plc (CIK 1530804) — Q2 2026 earnings releases dated August 4 and August 5, 2026, the June 24, 2026 consent decree 8-K, the January 26, 2026 Fuzhou closure release, and financing 8-Ks from September 2025 through March 2026. Price and share-count data as of August 26, 2026. Non-GAAP measures (adjusted EBITDA, adjusted EPS, free cash flow, net leverage) are as defined by each company and are not comparable across issuers without adjustment. This page is research notes, not investment advice.